Noruxol (Collagenase Clostridium Histolyticum, Protease)

The collagenase component selectively cleaves collagen fibers and other extracellular matrix proteins within necrotic tissue. This enzymatic breakdown reduces the bulk of dead tissue, exposing viable tissue and promoting granulation, which accelerates the natural wound‑healing cascade.

The dosage and frequency of Noruxol are determined by the prescribing clinician based on wound size, depth, and patient condition. The prescriber will specify the amount of product to apply and the interval, typically ranging from once daily to multiple applications per week.

The pregnancy category for Noruxol is listed as unknown. It should only be used during pregnancy or lactation if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To request Noruxol, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.

Compared with mechanical debridement, Noruxol offers a non‑invasive, selective enzymatic approach that spares healthy tissue. Relative to other enzymatic agents such as papain‑urea, collagenase has a higher specificity for collagen, often resulting in more controlled debridement and fewer adverse skin reactions.

Noruxol should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing. No refrigeration is required.

Noruxol is applied topically to the wound surface as directed by the prescriber. The clinician cleans the wound, applies the specified amount of product, and may cover it with a suitable dressing. The frequency of application is based on the wound’s response and the physician’s instructions.

Serious risks include severe allergic reactions such as anaphylaxis, extensive skin necrosis beyond the intended area, and deep tissue infections like cellulitis. Patients should be monitored for signs of systemic hypersensitivity, rapid tissue loss, or worsening of the wound, and treatment should be stopped if these occur.

Noruxol is contraindicated in patients with known hypersensitivity to collagenase, protease enzymes, or any excipients in the formulation. It should also be avoided on healthy, non‑necrotic skin, in wounds without a necrotic component, and in individuals where the risk of allergic reaction outweighs potential benefit.